236 related articles for article (PubMed ID: 33978635)
1. Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.
Osum SH; Coutts AW; Duerre DJ; Tschida BR; Kirstein MN; Fisher J; Bell WR; Delpuech O; Smith PD; Widemann BC; Moertel CL; Largaespada DA; Watson AL
Neurooncol Adv; 2021; 3(1):vdab020. PubMed ID: 33978635
[TBL] [Abstract][Full Text] [Related]
2. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Anderson MK; Johnson M; Thornburg L; Halford Z
Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
[TBL] [Abstract][Full Text] [Related]
3. Case report: Revascularization failure in NF1-related moyamoya syndrome after selumetinib: A possible pathophysiological correlation?
Chelleri C; Scala M; De Marco P; Traverso M; Ognibene M; Bruno I; Piccolo G; Striano P; Severino M; Zara F; Diana MC; Pavanello M
Front Pediatr; 2023; 11():1051026. PubMed ID: 36923276
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
6. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
7. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
[TBL] [Abstract][Full Text] [Related]
8. Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.
Osum SH; Oribamise EI; Corbière SMAS; Taisto M; Jubenville T; Coutts A; Kirstein MN; Fisher J; Moertel C; Du M; Bedwell D; Largaespada DA; Watson AL
Mol Ther Nucleic Acids; 2023 Sep; 33():227-239. PubMed ID: 37520682
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
[No Abstract] [Full Text] [Related]
10. Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
Suenobu S; Terashima K; Akiyama M; Oguri T; Watanabe A; Sugeno M; Higashimori M; So K; Nishida Y
Neurooncol Adv; 2023; 5(1):vdad054. PubMed ID: 37287695
[TBL] [Abstract][Full Text] [Related]
11. Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas.
Viskochil D; Wysocki M; Learoyd M; Sun P; So K; Evans A; Lai F; Hernàndez HS
Neurooncol Adv; 2024; 6(1):vdae036. PubMed ID: 38721358
[TBL] [Abstract][Full Text] [Related]
12. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas.
Jackson S; Baker EH; Gross AM; Whitcomb P; Baldwin A; Derdak J; Tibery C; Desanto J; Carbonell A; Yohay K; O'Sullivan G; Chen AP; Widemann BC; Dombi E
Neurooncol Adv; 2020; 2(1):vdaa095. PubMed ID: 32939452
[TBL] [Abstract][Full Text] [Related]
13. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
[TBL] [Abstract][Full Text] [Related]
14. Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management.
Borgia P; Piccolo G; Santangelo A; Chelleri C; Viglizzo G; Occella C; Minetti C; Striano P; Diana MC
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542016
[No Abstract] [Full Text] [Related]
15. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis 1 (von Recklinghausen Disease).
Yoshida Y
Keio J Med; 2023 Aug; ():. PubMed ID: 37635082
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Cardiac Function by Echocardiographic Global Longitudinal Strain in a Cohort of Children with Neurofibromatosis Type 1 Treated with Selumetinib.
Caiffa T; Tessitore A; Magnolato A; Petz M; Bobbo M; Chicco D; D'Agata Mottolese B; Porcari A; Barbi E; Sinagra G; Bruno I
Paediatr Drugs; 2023 Mar; 25(2):217-224. PubMed ID: 36529809
[TBL] [Abstract][Full Text] [Related]
18. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
[TBL] [Abstract][Full Text] [Related]
19. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
Gross AM; Dombi E; Widemann BC
Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
[TBL] [Abstract][Full Text] [Related]
20. Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma.
Mukhopadhyay S; Maitra A; Choudhury S
Curr Med Res Opin; 2021 May; 37(5):789-794. PubMed ID: 33683166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
